Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NKGen Biotech, Inc. - Common Stock (NQ: NKGN )

0.8741 +0.0041 (+0.47%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NKGen Biotech, Inc. - Common Stock

< Previous 1 2 3 Next >
NKGen Biotech Selected as Stalking Horse Bidder for NKMax
From NKGen Biotech, Inc.
Via GlobeNewswire
NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel
From NKGen Biotech, Inc.
Via GlobeNewswire
NKGN Stock Earnings: NKGen Biotech Reported Results for Q1 2024
NKGen Biotech just reported results for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From NKGen Biotech
Via GlobeNewswire
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From NKGen Biotech
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
From NKGen Biotech, Inc.
Via GlobeNewswire
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
From NKGen Biotech
Via GlobeNewswire
Why Tellurian Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock
Intuitive Surgical stock is falling on Thursday even after shares of ISRG got an increased price target from Barclays analysts. 
Via InvestorPlace
WBD Stock Pops as Warner Bros. Considers Streaming Spinoff
Warner Bros. stock is rising on Thursday as reports about a potential spinoff of its streaming division embolden WBD investors. 
Via InvestorPlace
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
NKGen Biotech stock is up Thursday as NKGN holders react to plans for a presentation at the Alzheimer’s Association International Conference. 
Via InvestorPlace
Why NKGen Biotech (NKGN) Stock Is Skyrocketing
NKGen Biotech shares are trading higher by 32.5% Thursday morning. The company announced it will present new SNK01 biomarker data at the Alzheimer's Association International Conference. 
Via Benzinga
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
From NKGen Biotech
Via GlobeNewswire
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
From NKGen Biotech
Via GlobeNewswire
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.